biostudies-literatureUnknown12Hu YNational Natural Science Foundation of ChinaThe combination of vonoprazan (VPZ) and amoxicillin (VA therapy) has been shown to achieve acceptable eradication rates for <i>Helicobacter pylori</i> (<i>H. pylori</i>). Herein, our aim was to explore the short-term effect of VA therapy on the gut microbiota and short-chain fatty acids (SCFAs) using human fecal samples. A total of 119 <i>H. pylori</i>-positive patients were randomized into low- or high-dose VA therapy (i.e., amoxicillin 1 g b.i.d. or t.i.d. and VPZ 20 mg b.i.d.) for 7 or 10 days. Thirteen <i>H. pylori</i>-negative patients served as controls. Fecal samples were collected from <i>H. pylori</i>-positive and <i>H. pylori</i>-negative patients. The gut microbiota and SCFAs were analyzed using 16S rRNA gene sequencing and gas chromatography-mass spectrometry, respectively. The gut microbiota in <i>H. pylori</i>-positive patients exhibited increased richness, diversity, and better evenness than matched patients. Fifty-three patients studied before and after <i>H. pylori</i> eradication were divided into low (L-VA) and high (H-VA) amoxicillin dose groups. The diversity and composition of the gut microbiota among L-VA patients exhibited no differences at the three time points. However, among H-VA patients, diversity was decreased, and the microbial composition was altered immediately after H-VA eradication but was restored by the confirmation time point. The decreased abundance of <i>Anaerostipes</i>, <i>Dialister</i>, and <i>Lachnospira</i> induced by H-VA was associated with altered SCFA levels. VA dual therapy for <i>H. pylori</i> eradication has minimal negative effects on gut microbiota and SCFAs.Frontiers in cellular and infection microbiology881968https://www.ebi.ac.uk/biostudies/studies/S-EPMC9201212biostudies-literatureAltered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for <i>Helicobacter pylori</i> Eradication.PMC9201212He CHu YZhu ZHXie YLu NHZhu YLi NSPeng CShu XXu XXie COuyang YBfalseAltered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for <i>Helicobacter pylori</i> Eradication.The combination of vonoprazan (VPZ) and amoxicillin (VA therapy) has been shown to achieve acceptable eradication rates for <i>Helicobacter pylori</i> (<i>H. pylori</i>). Herein, our aim was to explore the short-term effect of VA therapy on the gut microbiota and short-chain fatty acids (SCFAs) using human fecal samples. A total of 119 <i>H. pylori</i>-positive patients were randomized into low- or high-dose VA therapy (i.e., amoxicillin 1 g b.i.d. or t.i.d. and VPZ 20 mg b.i.d.) for 7 or 10 days. Thirteen <i>H. pylori</i>-negative patients served as controls. Fecal samples were collected from <i>H. pylori</i>-positive and <i>H. pylori</i>-negative patients. The gut microbiota and SCFAs were analyzed using 16S rRNA gene sequencing and gas chromatography-mass spectrometry, respectively. The gut microbiota in <i>H. pylori</i>-positive patients exhibited increased richness, diversity, and better evenness than matched patients. Fifty-three patients studied before and after <i>H. pylori</i> eradication were divided into low (L-VA) and high (H-VA) amoxicillin dose groups. The diversity and composition of the gut microbiota among L-VA patients exhibited no differences at the three time points. However, among H-VA patients, diversity was decreased, and the microbial composition was altered immediately after H-VA eradication but was restored by the confirmation time point. The decreased abundance of <i>Anaerostipes</i>, <i>Dialister</i>, and <i>Lachnospira</i> induced by H-VA was associated with altered SCFA levels. VA dual therapy for <i>H. pylori</i> eradication has minimal negative effects on gut microbiota and SCFAs.2022-01-01T00:00:00Z20222026-05-10T01:41:26.03Z2025-02-19T02:57:53.492ZS-EPMC92012123571933810.3389/fcimb.2022.881968